Technique for energy decomposition in the study of "receptor- ligand" complexes

Journal of Chemical Information and Modeling

Volumn 49, Issue 6, 2009, Pages 1389-1406

  Potemkin, Vladimir A ^a   Pogrebnoy, Alexander A ^a   Grishina, Maria A ^a  

^a SOUTH URAL STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROGEN BONDS; LIGANDS;

ENERGY DECOMPOSITION; HYDROGEN BOND ENERGY; RECEPTOR LIGANDS;

COMPLEXATION;

ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; LIGAND;

ALGORITHM; ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; ENZYME ACTIVE SITE; HYDROGEN BOND; METABOLISM; THERMODYNAMICS;

ALGORITHMS; ANTINEOPLASTIC AGENTS; CATALYTIC DOMAIN; ENZYME INHIBITORS; HYDROGEN BONDING; LIGANDS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; THERMODYNAMICS;

EID: 67650077389     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci800405n     Document Type: Article

References (81)

1. Evrard, G. X.; Langer, G. G.; Perrakis, A.; Lamzin, V. S. Assessment of automatic ligand building in ARP/wARP. Acta Crystallogr. 2007, D63, 108-117.
2. Rawal, R. K.; Kumar, A.; Siddiqi, M. I.; Katti, S. B. Molecular docking studies on 4-thiazolidinones as HIV-1RT inhibitors. J. Mol. Model. 2007, 13, 155-161.
3. Cai, W.; Xia, B.; Shao, X.; Guo, Q.; Maigret, B. Pan, Zh. Effect of R-cyclodextrin coating on electronic properties of molecular wires. Chem. Phys. Lett. 2001, 342, 387-396.
4. Dadrass, O. G.; Sobhani, A. M.; Shafiee, A.; Mahmoudian, M. Flexible ligand docking studies of matrix metalloproteinase inhibitors using Lamarckian genetic algorithm. Daru 2004, 12, 1-10.
5. Gorse, A.-D.; Gready, J. E. Molecular dynamics simulations of the docking of substituted N5-deazapterins to dihydrofolate reductase. Protein Eng. 1997, 10, 23-30.
6. Laskowski, R. A.; Rullmann, J. A.; MacArthur, M. W.; Kaptein, R.; Thornton, J. M. AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. J. Biomol. NMR 1996, 8, 477-486.
7. Westbrook, J.; Feng, Z.; Jain, Sh.; Bhat, N.; Thanki, N.; Ravichandran, V.; Gilliland, G. L.; Bluhm, W.; Weissig, H.; Greer, D. S.; Bourne, Ph. E.; Berman, H. M. The Protein Data Bank: unifying the archive. Nucleic Acids Res. 2002, 30, 245-248.
8. Venclovas, C.; Ginalski, K.; Kang, Ch. Sequence-structure mapping errors in the PDB: OB-fold domains. Protein Sci. 2004, 13, 1594-1602.
9. Sippl, M. J. Recognition of errors in three-dimensional structures of proteins. Proteins 1993, 17, 355-362.
10. Laskowski, R. A.; McArthur, M. W.; Moss, D. S.; Thornton, J. M. PROCHECK - a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 1993, 26, 283-291.
11. Hooft, R. W.; Sander, C.; Vriend, G. Verification of Protein Structures: Side-Chain Planarity. J. Appl. Crystallogr. 1996, 29, 714-716.
12. Hooft, R. W.; Vriend, G.; Sander, C.; Abola, E. E. Errors in protein structures. Nature 1996, 381, 272-272.
13. Gilmore, T.; Graham, A. G.; Grob, P. M.; Hickey, E. R.; Moss, N.; Pav, S.; Regan, J. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat. Struct. Biol. 2002, 9, 268-272.
14. Wang, Z.; Canagarajah, B. J.; Boehm, J. C.; Kassisa, S.; Cobb, M. H.; Young, P. R.; Abdel-Meguid, S.; Adams, J. L.; Goldsmith, E. J. Structural basis of inhibitor selectivity in MAP kinases. Structure 1998, 6, 1117-1128.
15. Shewchuk, L.; Hassell, A.; Wisely, B.; Rocque, W.; Holmes, W.; Veal, J.; Kuyper, L. F. Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilino-quinazolines bound to cyclin-dependent kinase 2 and p38 kinase. J. Med. Chem. 1999, 43, 133-138.
16. Iwase, K.; Hirono, Sh. Estimation of active conformations of drugs by a new molecular superposing procedure. J. Comput.-Aided Mol. Des. 1999, 13, 499-512.
17. Lee, M. C.; Yang, R.; Daun, Y. Comparison between Generalized-Born and Poisson-Boltzmann methods in Physics Based Scoring Functions for Protein Structure Prediction. J. Mol. Model. 2005, 12, 101-110.
18. Koehler, R. T.; Villar, H. O. Statistical relationships among docking scores for different protein binding sites. J. Comput.-Aided Mol. Des. 2000, 14, 23-37.
19. Olsen, L.; Petterson, I.; Hemmingsen, L. Docking and scoring of metallo-beta-lactamase inhibitors. J. Comput.-Aided Mol. Des. 2004, 18, 287-302.
20. Ha, S.; Andreani, R.; Robbins, A.; Muegge, I. Evaluation of docking/scoring approaches: a comparative study based on MMP3 inhibitors. J. Comput.-Aided Mol. Des. 2000, 14, 435-448.
21. Kubinyi, H. Combinatorial and computational approaches in structure-based drug design. Curr. Opin. Drug Discovery Dev. 1998, 1, 16-27.
22. Rarey, M.; Kramer, B.; Lengauer, T.; Klebe, G. A fast flexible docking method using an incremental construction algorithm. J. Mol. Biol. 1996, 261, 470-489.
23. Kubinyi, H.; Hamprecht, F. A.; Mietzner, T. Three-dimensional quantitative similarity-activity relationships (3D QSiAR) from SEAL similarity matrices. J. Med. Chem. 1998, 41, 2553-2564.
24. Golbraikh, A.; Tropsha, A. Beware of q2! J. Mol. Graph. Modell. 2002, 20, 269-276.
25. Novellino, E.; Fattorusso, C.; Greco, G. Use of comparative molecular field analysis and cluster analysis in series design. Pharm. Acta Helv. 1995, 70, 149-154.
26. Norinder, U. Single Domain Mode Variable Selection in 3D QSAR Applications. J. Chemom. 1996, 10, 95-105.
27. Kubinyi, H. A. general view on similarity and QSAR studies. In Computer-Assisted Lead Finding and Optimization, 1st ed.; van de Waterbeemd, H., Testa, B., Folkers, G., Eds.; Wiley-VCH: Zurich, Switzerland, 1997; pp 9-28.
28. Cosgrove, D. A.; Bayada, D. M.; Johnson, A. P. A novel method of aligning molecules by local surface shape similarity. J. Comput.-Aided Mol. Des. 2000, 14, 573-591.
29. Potemkin, V. A.; Bartashevich, E. V.; Grishina, M. A.; Guccione, S. In Rational Approaches to Drug Design; Proceedings of the 13th European Symp. on Quantitative Structure-Activity Relationships, Dusseldorf, Germany, 2000; Holtje, H.-D.; Sippl, W., Eds.; Prous Science Publishers: Barcelona, Spain, 2001; pp 349-353.
30. Potemkin, V. A.; Grishina, M. A.; Bartashevich, E. V. Modeling of drug molecule orientation within a receptor cavity in the BiS algorithm framework. J. Struct. Chem. 2007, 48, 155-160.
31. Potemkin, V. A.; Arslambekov, R. M.; Bartashevich, E. V.; Grishina, M. A.; Belik, A. V.; Perspicace, S.; Guccione, S. Multiconformational Method for Analyzing the Biological Activity of Molecular Structures. J. Struct. Chem. 2002, 43, 1045-1049.
32. Potemkin, V. A.; Grishina, M. A. A new paradigm for pattern recognition of drugs. J. Comput.-Aided. Mol. Des. 2008, 22, 489-505.
33. Potemkin, V. A.; Bartashevich, E. V.; Belik, A. V. New approaches to prediction of thermodynamic parameters of substances using molecular data. Russ. J. Phys. Chem. 1996, 70, 411-416.
34. Mikuchina, K.; Potemkin, V.; Grishina, M.; Laufer, S. 3D QSAR analysis and pharmacophore modelling of p38 MAP kinase inhibitors using BiS algorithm. Arch. Pharm. Pharm. Med. Chem. 2002, 335, C74.
35. Grishina, M. A.; Mikushina, K. M.; Potemkin, V. A. In Proceedings of the 16th European Symposium on Quantitative Structure-Activity Relationships and Molecular Modelling; Proceedings of the 16th European Symposium on Quantitative Structure-Activity Relationships and Molecular Modelling, Mediterranean Sea, Italy, 2006; Cruciani G., Ed.; ITALGRAF: Rome, 2006; p 241.
36. Tsirelson, V.; Stash, A.; Zhurova, E.; Zhurov, V.; Pinkerton, A. A.; Zavodnik, V.; Shutalev, A.; Gurskaya, G.; Rykounov, A.; Potemkin, V. Electron-density Properties of the Functionally-substituted Hydro-pyrimidines. Acta Crystallogr., Sect. A: Found. Crystallogr. 2005, A61, C427.
37. Grant, J. A.; Pickup, B. T. A Gaussian description of molecular shape. J. Phys. Chem. 1995, 99, 3503-3510.
38. Grant, J. A.; Gallardo, M. A.; Pickup, B. T. A fast method of molecular shape comparison: A simple application of a Gaussian description of molecular shape. J. Comput. Chem. 1996, 17, 1653-1666.
39. Connolly, M. L. Analytical molecular surface calculation. J. Appl. Crystallogr. 1983, 16, 548-558.
40. Connolly, M. L. Computation of molecular volume. J. Am. Chem. Soc. 1985, 107, 1118-1124.
41. Mortier, W. J.; Van Genechten, K.; Gasteiger, J. Electronegativity equalization-application and parametrization. J. Am. Chem. Soc. 1985, 107, 829-835.
42. Grishina, M. A.; Bartashevich, E. V.; Potemkin, V. A.; Belik, A. V. Genetic Algorithm for Predicting Structures and Properties of Molecular Aggregates in Organic Substances. J. Struct. Chem. 2002, 43, 1040-1043.
43. Bartashevich, E. V.; Potemkin, V. A.; Grishina, M. A.; Belik, A. V. A Method for Multiconformational Modeling of the Three-Dimensional Shape of a Molecule. J. Struct. Chem. 2002, 43, 1033-1039.
44. Kirkwood, J. G. Quantum Statistics of Almost Classical Assemblies. Phys. Rev. 1933, 44, 31-37.
45. Voorman, R. L.; Maio, S. M.; Hauer, M. J.; Sanders, P. E.; Payne, N. A.; Ackland, M. J. Metabolism of Delavirdine, a Human Immunodeficiency Virus Type-1 Reverse Transcriptase Inhibitor, by Microsomal Cytochrome P450 in Humans, Rats, and Other Species: Probable Involvement of CYP2D6 and CYP3A. Drug Metab. Dispos. 1998, 26, 631-639.
46. Kudo, S.; Okumura, H.; Miyamoto, G.; Ishizaki, T. Cytochrome P-450 Isoforms Involved in Carboxylic Acid Ester Cleavage of Hantzsch Pyridine Ester of Pranidipine. Drug Metab. Dispos. 1999, 27, 303-308.
47. Patten, C. J.; Thomas, P. E.; Guy, R. L.; Lee, M.; Gonzalez, F. J.; Guengerich, F. P.; Yang, C. S. Cytochrome P450 enzymes involved in acetaminophen activation by rat and human liver microsomes and their kinetics. Chem. Res. Toxicol. 1993, 6, 511-518.
48. Wienkers, L. C.; Steenwyk, R. C.; Sanders, P. E.; Pearson, P. G. Biotransformation of tirilazad in human: 1. Cytochrome P450 3A-mediated hydroxylation of tirilazad mesylate in human liver microsomes. J. Pharmacol. Exp. Ther. 1996, 277, 982-990.
49. Ghosal, A.; Satoh, H.; Thomas, P. E.; Bush, E.; Moore, D. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450. Drug Metab. Dispos. 1996, 24, 940-947.
50. Nielsen, T. L.; Rasmussen, B. B.; Flinois, J. P.; Beaune, P.; Brosen, K. In Vitro Metabolism of Quinidine: The (3S)-3-Hydroxylation of Quinidine Is a Specific Marker Reaction for Cytochrome P-4503A4 Activity in Human Liver Microsomes. J. Pharmacol. Exp. Ther. 1999, 289, 31-37.
51. Rochat, B.; Amey, M.; Gillet, M.; Meyer, U. A.; Baumann, P. Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics 1997, 7, 1-10.
52. Ishiguro, N.; Senda, C.; Kishimoto, W.; Sakai, K.; Funae, Y.; Igarashi, T. Identification of CYP3A4 as the predominant isoform responsible for the metabolism of ambroxol in human liver microsomes. Xenobiotica 2000, 30, 71-80.
53. Olesen, O. V.; Linnet, K. Metabolism of the tricyclic antidepressant amitriptyline by cDNA-expressed human cytochrome P450 enzymes. Pharmacology 1997, 55, 235-243.
54. Haaz, M. C.; Rivory, L.; Richã, C.; Vernillet, L.; Robert, J. Metabolism of CPT-11 by Human Hepatic Microsomes: Participation of Cytochrome P-450 3A and Drug Interactions. Cancer. Res. 1998, 58, 468-472.
55. Koudriakova, T.; Iatsimirskaia, E.; Utkin, I.; Gangl, E.; Vouros, P.; Storozhuk, E.; Orza, D.; Marinina, J.; Gerber, N. Metabolism of the Human Immunodeficiency Virus Protease Inhibitors Indinavir and Ritonavir by Human Intestinal Microsomes and Expressed Cytochrome P4503A4/3A5: Mechanism-Based Inactivation of Cytochrome P4503A by Ritonavir. Drug Metab. Dispos. 1998, 26, 552-561.
56. Shou, M.; Martinet, M.; Korzekwa, K. R.; Krausz, K. W.; Gonzalez, F. J.; Gelboin, H. V. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics 1998, 8, 391-401.
57. Yaïch, M.; Popon, M.; Mãdard, Y.; Aigrain, E. J. In-vitro cytochrome P450 dependent metabolism of oxybutynin to N-deethyloxybutynin in humans. Pharmacogenetics 1998, 8, 449-451.
58. Dupont, I.; Berthou, F.; Bodenez, P.; Bardou, L.; Guirriec, C.; Stephan, N.; Dreano, Y.; Lucas, D. Involvement of cytochromes P450 2E1 and 3A4 in the 5-hydroxylation of salicylate in humans. Drug Metab. Dispos. 1999, 27, 322-326.
59. Tracy, T. S.; Korzekwa, K. R.; Gonzalez, F. J.; Wainer, I. W. Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil. Br. J. Clin. Pharmacol. 1999, 47, 545-552.
60. Zhang, Q. Y.; Dunbar, D.; Kaminsky, L. Human cytochrome P-450 metabolism of retinals to retinoic acids. Drug Metab. Dispos. 2000, 28, 292-297.
61. Gantenbein, M.; Attolini, L.; Bruguerolle, B.; Villard, P. H.; Puyoou, F.; Durand, A.; Lacarelle, B.; Hardwigsen, J.; Le-Treut, Y. P. Oxidative metabolism of bupivacaine into pipecolylxylidine in humans is mainly catalyzed by CYP3A. Drug Metab. Dispos. 2000, 28, 383-385.
62. Prakash, C.; Kamel, A.; Cui, D.; Whalen, R. D.; Miceli, J. J.; Tweedie, D. Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. Br. J. Clin. Pharmacol. 2000, 49, 35S-42S.
63. Tang, C.; Shou, M.; Mei, Q.; Rushmore, T. H.; Rodrigues, A. D. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. J. Pharmacol. Exp. Ther. 2000, 293, 453-459.
64. Bournique, B.; Lambert, N.; Boukaiba, R.; Martinet, M. In vitro metabolism and drug interaction potential of a new highly potent anticytomegalovirus molecule, CMV423 (2-chloro 3-pyridine 3-yl 5,6,7,8-tetrahydroindolizine I-carboxamide). Br. J. Clin. Pharmacol. 2001, 52, 53-63.
65. Molden, E.; Asberg, A.; Christensen, H. Desacetyl-Diltiazem Displays Severalfold Higher Affinity to CYP2D6 Compared with CYP3A4. Drug Metab. Dispos. 2002, 30, 1-3.
66. Zhou, Q.; Yao, T. W.; Yu, Y. N.; Zeng, S. Stereoselective metabolism of propafenone by human liver CYP3A4 expressed in transgenic Chinese hamster CHL cells lines. Acta Pharmacol. Sin. 2001, 22, 944-948.
67. Zhao, G.; Allis, J. W. Kinetics of bromodichloromethane metabolism by cytochrome P450 isoenzymes in human liver microsomes. Chem. Biol. Interact. 2002, 140, 155-168.
68. Kalgutkar, A. S.; Taylor, T. J.; Venkatakrishnan, K.; Isin, E. M. Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway. Drug Metab. Dispos. 2003, 31, 243-249.
69. Zhang, W.; Ramamoorthy, Y.; Tyndale, R. F.; Sellers, E. M. Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. Drug Metab. Dispos. 2003, 31, 768-772.
70. Rodrigues, A. D.; Mulford, D. J.; Lee, R. D.; Surber, B. W.; Kukulka, M. J.; Ferrero, J. L.; Thomas, S. B.; Shet, M. S.; Estabrook, R. W. In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices. Drug Metab. Dispos. 1995, 23, 765-775.
71. Wang, R. W.; Newton, D. J.; Scheri, T. D.; Lu, A. Y. H. Human cytochrome P450 3A4-catalyzed testosterone 6-hydroxylation and erythromycin N-demethylation: competition during catalysis. Drug Metab. Dispos. 1997, 25, 502-507.
72. Ekroos, M.; Sjogren, T. Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 13682-13687.
73. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank. Nucleic Acids Res. 2000, 28, 235-242.
74. Williams, P. A.; Cosme, J.; Vinkovic, D. M.; Ward, A.; Angove, H. C.; Day, P. J.; Vonrhein, C.; Tickle, I. J.; Jhoti, H. Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science 2004, 305, 683-686.
75. Rozhansky, V. A.; Tsendin, L. D. Transport Phenomena in Partially Ionized Plasma; Taylor & Francis: London and New York, 2001; p 469.
76. Sinyaev, A. A.; Grishina, M. A.; Potemkin, V. A. Theoretical study of solvent influence on the regiospecificity of the reaction of 3-phenyl-s-tetrazine with ketene-N, N-aminal. ARKIVOC 2004, XI, 43-52.
77. Varghese, J. N.; Smith, P. W.; Sollis, S. L.; Blick, T. J.; Sahasrabudhe, A.; McKimm-Breschkin, J. L.; Colman, P. M. Drug design against a shifting target: A structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase. Structure (London) 1998, 6, 735-746.
78. Dombroski, M. A.; Letavic, M. A.; McClure, K. F.; Barberia, J. T.; Carty, T. J.; Cortina, S. R.; Csiki, C.; Dipesa, A. J.; Elliott, N. C.; Gabel, C. A.; Jordan, C. K.; Labasi, J. M.; Martin, W. H.; Peese, K. M.; Stock, I. A.; Svensson, L.; Sweeney, F. J.; Yu, C. H. Benzimidazolone p38 inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 919-923.
79. National Cancer Institute database. DTP/2D and 3D Structural Information. http://dtp.nci.nih.gov/docs/3d-database/Structural-information/structural-data. html (accessed December 18, 2008).
80. van Osdol, W. W.; Myers, T. G.; Paull, K. D.; Kohn, K. W.; Weinstein, J. N. Use of the Kohonen self-organizing map to study the mechanisms of action of chemotherapeutic agents. J. Natl. Cancer Inst. 1994, 86, 1853-1859.
81. Sawaya, M. R.; Kraut, J. Loop and subdomain movements in the mechanism of Escherichia coli dihydrofolate reductase: crystallographic evidence. Biochemistry 1997, 36, 586-603.